Similar articles for PMID: 32014924

Year	Number of Results
2010	1
2011	2
2012	3
2013	3
2014	5
2015	11
2016	16
2017	19
2018	21
2019	15
2020	6
2021	2
2022	2
2023	0

1

Olaparib Potentiates Anticancer Drug Cytotoxicity via 53BP1 in Oesophageal Squamous Cell Carcinoma Cells.

Miyamoto K, Minegaki T, Hirano S, Hayashi I, Tsujimoto M, Nishiguchi K. Miyamoto K, et al. Anticancer Res. 2020 Feb;40(2):813-823. doi: 10.21873/anticanres.14013. Anticancer Res. 2020. PMID: 32014924

2

Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.

Miyamoto K, Minegaki T, Tanahashi M, Yamamoto A, Moriyama Y, Wada A, Matsumoto A, Ota K, Tanaka M, Masuda U, Tsujimoto M, Nishiguchi K. Miyamoto K, et al. Anticancer Res. 2019 Apr;39(4):1813-1820. doi: 10.21873/anticanres.13288. Anticancer Res. 2019. PMID: 30952721

3

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.

Kageyama SI, Junyan D, Hojo H, Motegi A, Nakamura M, Tsuchihara K, Akimoto T. Kageyama SI, et al. J Radiat Res. 2020 Mar 23;61(2):177-186. doi: 10.1093/jrr/rrz088. J Radiat Res. 2020. PMID: 31976528 Free PMC article.

4

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ. Min A, et al. Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y. Breast Cancer Res. 2015. PMID: 25888415 Free PMC article.

5

Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.

Ma X, Dang C, Min W, Diao Y, Hui W, Wang X, Dai Z, Wang X, Kang H. Ma X, et al. Breast Cancer Res Treat. 2019 Jul;176(1):109-117. doi: 10.1007/s10549-019-05189-w. Epub 2019 Apr 15. Breast Cancer Res Treat. 2019. PMID: 30989461

6

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.

Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L. Lin X, et al. J Exp Clin Cancer Res. 2018 Jun 28;37(1):129. doi: 10.1186/s13046-018-0790-7. J Exp Clin Cancer Res. 2018. PMID: 29954437 Free PMC article.

7

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.

Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B. Hong R, et al. BMC Cancer. 2016 Sep 9;16(1):725. doi: 10.1186/s12885-016-2754-7. BMC Cancer. 2016. PMID: 27613518 Free PMC article.

8

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.

Lai SW, Bamodu OA, Chen JH, Wu AT, Lee WH, Chao TY, Yeh CT. Lai SW, et al. Cells. 2020 Apr 8;9(4):911. doi: 10.3390/cells9040911. Cells. 2020. PMID: 32276472 Free PMC article.

9

Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.

Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP. Marijon H, et al. Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20. Biomed Pharmacother. 2018. PMID: 29902865

10

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH. Yuan B, et al. Cancer Lett. 2017 Feb 1;386:47-56. doi: 10.1016/j.canlet.2016.11.010. Epub 2016 Nov 12. Cancer Lett. 2017. PMID: 27847302

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed